STCube, developing the first-in-class immune checkpoint inhibitor Nelmastobat with a novel mechanism of action, continues follow-up negotiations for global technology licensing in the United States.
On the 27th, STCube announced that it will participate in the world's largest pharmaceutical and biotech partnering event, BIO International Convention (BIO USA) 2024.
At BIO USA, STCube will hold one-on-one partnering meetings with numerous global pharmaceutical companies. They will share research results on Nelmastobat and its clinical trials, as well as discuss business development opportunities.
STCube is developing Nelmastobat (hSTC810), an anti-BTN1A1 antibody therapeutic targeting BTN1A1, a new target in the immune checkpoint inhibitor market. For the treatment of extensive-stage small cell lung cancer, known as a difficult-to-treat cancer, STCube is conducting a Phase 1b/2 clinical trial combining Nelmastobat with chemotherapy. Simultaneously, they are conducting investigator-initiated clinical trials targeting patients with metastatic late-stage colorectal cancer.
An STCube representative stated, “Small cell lung cancer targeted by Nelmastobat and MSS (microsatellite stable) metastatic colorectal cancer have a significant number of patients, yet existing standard treatment options are limited. Because these are difficult-to-treat cancers where many drugs have struggled to expand indications, the need and interest in new drug development are very high in this market.”
They added, “As the clinical trials are progressing as expected, we are strategically approaching business development. As the trials advance, discussions for global technology licensing will accelerate even more.”
Small cell lung cancer accounts for about 10-15% of all lung cancers. According to the global pharmaceutical market research firm Evaluate Pharma, the worldwide small cell lung cancer market is expected to grow to $5.4 billion (approximately 7.4 trillion KRW) by 2028.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
